Thymic volume predicts long-term immune reconstitution in HIV-infected children treated with highly active antiretroviral therapy.

Highly active antiretroviral therapy (HAART) suppresses viral replication and augments CD4 T cell counts. HAART-associated immune restoration is often difficult to predict. We verified whether increases in CD4 cells, and particularly in cells of the naive phenotype, would be associated in HAART-treated children with thymic volume. Long-term immune reconstitution is significantly better in children with bigger thymuses at the initiation of HAART. Thymic volume has a strong predictive value for the immunological effect of HAART.

[1]  R. Hornung,et al.  Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  F. Parazzini,et al.  Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study , 2000, Journal of acquired immune deficiency syndromes.

[3]  V. Diehl,et al.  Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment? , 1999, AIDS.

[4]  R. Chaisson,et al.  Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs , 2001, AIDS.

[5]  C. Mackall,et al.  Pathways of T‐cell regeneration in mice and humans: implications for bone marrow transplantation and immmunotherapy , 1997, Immunological reviews.

[6]  M. Lederman,et al.  Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function , 2001, AIDS.

[7]  J. Roujeau,et al.  Patch testing in severe cutaneous adverse drug reactions, including Stevens‐Johnson syndrome and toxic epidermal necrolysis , 1996, Contact dermatitis.

[8]  F. Lori.  Hydroxyurea and HIV: 5 years later--from antiviral to immune-modulating effects. , 1999, AIDS.

[9]  J. Piette,et al.  Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea. , 1999, AIDS research and human retroviruses.

[10]  David A. Cooper,et al.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.

[11]  N. Klein,et al.  Immune repopulation after HAART in previously untreated HIV-1-infected children , 2000, The Lancet.

[12]  Ralph B. D'Agostino,et al.  Blood Pressure as a Risk Factor for Cardiovascular Disease The Framingham Study—30 Years of Follow‐up , 1989, Hypertension.

[13]  A. Telenti,et al.  Premature atherosclerosis in HIV-infected individuals – focus on protease inhibitor therapy , 2001, AIDS.

[14]  B. Haynes,et al.  The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. , 2000, Annual review of immunology.

[15]  Rob J. De Boer,et al.  Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation , 1998, Nature Medicine.

[16]  H. Hooijkaas,et al.  Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status , 2001, AIDS.

[17]  J L Sullivan,et al.  Effect of HIV on thymic function before and after antiretroviral therapy in children. , 2000, The Journal of infectious diseases.

[18]  D. Vittecoq,et al.  Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. , 1999, AIDS.

[19]  M. Lederman,et al.  Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. , 2000, The Journal of infectious diseases.

[20]  F. Malavasi,et al.  Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity , 2001, AIDS.

[21]  Martin H. Abramson,et al.  Complete Drug Reference , 1996 .